National Health Act 1953 - Declaration under sub-section 85(2AA) (18/07/1988)

Overview

The National Health Act 1953 was enacted to establish a framework for the administration and provision of health services in Australia. This legislation was introduced to address the need for a coordinated approach to healthcare services and to facilitate the provision of benefits, including pharmaceutical benefits, to the Australian population. The Act is overseen by the Parliament of Australia, which aims to ensure that health services are accessible and affordable for all Australians. The policy objective of the Act is to support the provision of health services through the establishment of a national health scheme, including the Pharmaceutical Benefits Scheme (PBS), which provides subsidised access to essential medications. This legislative instrument, made under sub-section 85(2AA) of the National Health Act 1953, declares certain drugs and medicinal preparations to no longer be subject to the provisions of Part VII of the Act, effectively removing them from the PBS schedule. This change came into effect on 1 August 1988, as declared by John Stewart Deeble, Acting First Assistant Secretary of the Health Benefits Division, and acting as the Delegate of the Minister of State for Community Services and Health.

Scope and Application

The National Health Act 1953, as amended through the legislative instrument F2008B00057, pertains specifically to the pharmaceutical benefits scheme by removing certain drugs and medicinal preparations from the list of those covered under Part VII of the Act. The scope of this particular Declaration applies to the drugs and medicinal preparations listed in the Schedule of the instrument, which includes specific compounds and extracts such as Aluminium Sodium Polyhydroxy Monocarbonate Hexitol Complex, Biperiden Lactate Injection, and various insect allergen extracts. This legislative instrument targets these particular substances to cease their classification under the Pharmaceutical Benefits, effective from 1 August 1988. The jurisdictional reach of this Act is nationwide, impacting all entities and individuals involved in the distribution, prescription, or use of these pharmaceuticals within Australia. The exclusion of these substances from the Pharmaceutical Benefits scheme means they will no longer be subsidised under the scheme, thereby affecting the pricing and accessibility for consumers and providers alike. The exclusion is precise and does not extend to other pharmaceuticals not listed in the Schedule, ensuring that only the specified items are affected by this legislative change.

Key Provisions

The key provisions of this Declaration under sub-section 85(2AA) of the National Health Act 1953 (sections referenced in parentheses) revolve around the cessation of the application of Part VII of the Act to certain drugs and medicinal preparations. The Declaration specifies that from 1 August 1958, the drugs and preparations listed in the Schedule will no longer be subject to the provisions of Part VII of the Act (sections 2 and Schedule). This means that these specific items will no longer be eligible for inclusion in the Pharmaceutical Benefits Scheme (PBS) or subject to the price controls and regulations outlined in Part VII of the Act. The obligations and requirements imposed by this Act on the parties or entities it governs include the necessity for the Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health, acting as the delegate of the Minister of State for Community Services and Health, to make such a declaration (section 85(2AA)). This declaration officially removes the specified drugs and preparations from the scope of Part VII of the Act, thereby altering their status regarding benefits, pricing, and regulation under the National Health Act. Failure to comply with the provisions set out in this Declaration could result in various civil or criminal consequences, depending on the nature and intent of the breach. For example, if entities or individuals continue to claim benefits or adhere to the regulations of Part VII for the listed drugs and preparations after the effective date of 1 August 1988, they could face penalties under the National Health Act. The specific penalties are not detailed in the provided text, but they typically include fines, imprisonment, or both, depending on the severity and intent of the breach. The exact penalties would be determined in accordance with the broader provisions of the National Health Act and any relevant subsidiary legislation.